Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Toll-like receptors: Roles in disease and therapy

Francisco A Bonilla, MD, PhD
Section Editor
E Richard Stiehm, MD
Deputy Editor
Anna M Feldweg, MD


The toll-like receptors (TLRs) are surface molecules on eukaryotic cells that detect and respond to microbial antigens. TLRs derive their name from homology to the Drosophila Toll molecule, an important component of an antifungal defense mechanism [1,2]. TLRs constitute a phylogenetically ancient system present in invertebrates and conserved through vertebrate evolution.

TLRs belong to a class of molecules known as pattern recognition receptors. The ligands for these receptors are components of pathogenic microbes and are often called pathogen-associated molecular patterns (PAMPs).

TLRs are frequently referred to as a system of nonspecific or "innate" immune defense (ie, the response is present and unchanging during the life of the organism and occurs in the same manner with every exposure to the pathogen) [3]. This is in contrast to specific or "adaptive" immunity (present only in vertebrates and mediated by lymphocytes), whereby the immune system response changes during the life of the host. Adaptive immune responses may be more vigorous (or suppressed) with each exposure to a pathogen depending upon encounters with that organism or others, and other conditions prevailing in the host. In vertebrates, although TLRs initiate protective functions that operate independently from adaptive immunity, they also modulate mechanisms having profound impact on the development of specific immune responses.

Innate immunity is reviewed separately. (See "An overview of the innate immune system" and "Immunity of the newborn".)


Different species have different numbers of distinct toll-like receptors (TLRs). At least 10 have been discovered in humans (TLR1-10) [1,2,4]. With the exception of TLR2, TLRs initiate signaling by homodimerization (eg, two identical TLRs brought together). TLR2 forms heterodimers with TLR1 or TLR6. Receptor structure/organization, ligands, and signaling are summarized in the table (table 1) and figure (figure 1).


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Fri Mar 20 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Schnare M, Rollinghoff M, Qureshi S. Toll-like receptors: sentinels of host defence against bacterial infection. Int Arch Allergy Immunol 2006; 139:75.
  2. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388:621.
  3. Gazzinelli RT, Denkers EY. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006; 6:895.
  4. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117:979.
  5. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168:554.
  6. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167:1882.
  7. Beutler BA. TLRs and innate immunity. Blood 2009; 113:1399.
  8. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499.
  9. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13:816.
  10. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446.
  11. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1.
  12. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000; 97:13766.
  13. Buwitt-Beckmann U, Heine H, Wiesmüller KH, et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006; 281:9049.
  14. Omueti KO, Beyer JM, Johnson CM, et al. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 2005; 280:36616.
  15. Massari P, Henneke P, Ho Y, et al. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002; 168:1533.
  16. LeBouder E, Rey-Nores JE, Rushmere NK, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171:6680.
  17. Schröder M, Bowie AG. TLR3 in antiviral immunity: key player or bystander? Trends Immunol 2005; 26:462.
  18. Tanabe M, Kurita-Taniguchi M, Takeuchi K, et al. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun 2003; 311:39.
  19. Pisegna S, Pirozzi G, Piccoli M, et al. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood 2004; 104:4157.
  20. Muroi M, Tanamoto K. Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. J Biol Chem 2006; 281:5484.
  21. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398.
  22. Sasu S, LaVerda D, Qureshi N, et al. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89:244.
  23. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003; 23:15.
  24. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099.
  25. Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33:2987.
  26. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526.
  27. Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598.
  28. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31:3026.
  29. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005; 174:2942.
  30. Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291:1544.
  31. Aliprantis AO, Yang RB, Weiss DS, et al. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000; 19:3325.
  32. Ayabe T, Ashida T, Kohgo Y, Kono T. The role of Paneth cells and their antimicrobial peptides in innate host defense. Trends Microbiol 2004; 12:394.
  33. Birchler T, Seibl R, Büchner K, et al. Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 2001; 31:3131.
  34. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14:96.
  35. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675.
  36. Bowie A, Kiss-Toth E, Symons JA, et al. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 2000; 97:10162.
  37. Harte MT, Haga IR, Maloney G, et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003; 197:343.
  38. Bochud PY, Hawn TR, Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003; 170:3451.
  39. Schmitt C, Humeny A, Becker CM, et al. Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem 2002; 48:1661.
  40. Plantinga TS, Johnson MD, Scott WK, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 2012; 205:934.
  41. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766.
  42. von Aulock S, Schröder NW, Gueinzius K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188:938.
  43. van der Graaf C, Kullberg BJ, Joosten L, et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 2005; 30:264.
  44. Imahara SD, Jelacic S, Junker CE, O'Keefe GE. The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes. Genes Immun 2005; 6:37.
  45. Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23:e61.
  46. Edfeldt K, Bennet AM, Eriksson P, et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25:1447.
  47. Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005; 36:154.
  48. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185.
  49. Kolek MJ, Carlquist JF, Muhlestein JB, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148:1034.
  50. Morange PE, Tiret L, Saut N, et al. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet 2004; 12:1041.
  51. Fagerås Böttcher M, Hmani-Aifa M, Lindström A, et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114:561.
  52. Adjers K, Karjalainen J, Pessi T, et al. Epistatic effect of TLR4 and IL4 genes on the risk of asthma in females. Int Arch Allergy Immunol 2005; 138:251.
  53. Yang IA, Barton SJ, Rorke S, et al. Toll-like receptor 4 polymorphism and severity of atopy in asthmatics. Genes Immun 2004; 5:41.
  54. Heggelund L, Müller F, Lien E, et al. Increased expression of toll-like receptor 2 on monocytes in HIV infection: possible roles in inflammation and viral replication. Clin Infect Dis 2004; 39:264.
  55. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105:15.
  56. Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004; 173:5901.
  57. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103:1064.
  58. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105:1158.
  59. Walton KA, Hsieh X, Gharavi N, et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 2003; 278:29661.
  60. Gereda JE, Leung DY, Thatayatikom A, et al. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000; 355:1680.
  61. Yoshioka M, Fukuishi N, Iriguchi S, et al. Lipoteichoic acid downregulates FcepsilonRI expression on human mast cells through Toll-like receptor 2. J Allergy Clin Immunol 2007; 120:452.
  62. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15:410.
  63. Dong L, Li H, Wang S, Li Y. Different doses of lipopolysaccharides regulate the lung inflammation of asthmatic mice via TLR4 pathway in alveolar macrophages. J Asthma 2009; 46:229.
  64. Tizaoui K, Kaabachi W, Hamzaoui K, Hamzaoui A. Association of Single Nucleotide Polymorphisms in Toll-like Receptor Genes With Asthma Risk: A Systematic Review and Meta-analysis. Allergy Asthma Immunol Res 2015; 7:130.
  65. Several commercial laboratories offer testing for TLR function. Examples in the United States include ViracorIBT and ARUP.
  66. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321:691.
  67. Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010; 89:403.
  68. McDonald DR, Goldman F, Gomez-Duarte OD, et al. Impaired T-cell receptor activation in IL-1 receptor-associated kinase-4-deficient patients. J Allergy Clin Immunol 2010; 126:332.
  69. Ku CL, Yang K, Bustamante J, et al. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005; 203:10.
  70. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003; 299:2076.
  71. Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007; 204:2407.
  72. Bousfiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010; 135:204.
  73. The Toll-like receptor function assay (#0051589). www.aruplab.com (Accessed on February 11, 2010).
  74. Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317:1522.
  75. Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314:308.
  76. Jouanguy E, Zhang SY, Chapgier A, et al. Human primary immunodeficiencies of type I interferons. Biochimie 2007; 89:878.
  77. Zhang SY, Jouanguy E, Sancho-Shimizu V, et al. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 2007; 220:225.
  78. Oldfield V, Keating GM, Perry CM. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol 2005; 6:195.
  79. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152:939.
  80. Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42:724.
  81. Maletto BA, Rópolo AS, Liscovsky MV, et al. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice. Clin Immunol 2005; 117:251.
  82. Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004; 27:460.
  83. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24:693.
  84. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105:489.
  85. Weihrauch MR, Ansén S, Jurkiewicz E, et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 2005; 11:5993.
  86. Simons FE, Shikishima Y, Van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113:1144.
  87. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235.
  88. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445.